The oncology giant will pay $1.5 billion in upfront fees to co-develop a BioNTech drug that targets the proteins PD1 and VEGF.Bristol Myers Squibb is making sure it won’t miss out on a new type of cancer immunotherapy that’s drawn immense industry interest, announcing Monday an alliance with BioNTech on a bispecific antibody the German […]
